All In Biotech

Drug Trial Radar · NCT07674940

A Trial to Assess TEV-56286 at Different Doses in Healthy Participants

A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Escalating Dose Trial in Healthy Participants to Assess Pharmacokinetics, Safety, and Tolerability of TEV-56286 at Clinical and Supratherapeutic Doses

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

69

Planned (sponsor's estimate)

Start

Jun 26, 2026

Primary completion

Jan 15, 2027

Study completion Jan 22, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the trial is to evaluate the pharmacokinetics, safety, and tolerability of TEV-56286 at different doses. The main objective is to describe how TEV-56286 is absorbed, distributed, and removed from the body (the pharmacokinetics) following administration of TEV-56286 in single doses of increasing amounts and multiple doses in healthy participants. A secondary objective is to assess the safety of TEV-56286 and how well it is tolerated. The estimated duration for participants in Part 1 with Single Ascending Dose is approximately 58 days; including up to 45 days of screening, a 4-day in-clinic period, and follow-up 8+/-1 days post discharge from the clinical unit. The estimated duration for participants in Part 2 with Multiple Ascending Dose is approximately 64 days; including up to 45 days of screening, a 10-day in-clinic period, and follow-up 8+/-1 days post discharge from the clinical unit.

Conditions

  • Healthy Volunteers

Interventions

  • TEV-56286Drug

    oral administration

  • PlaceboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD: Time to maximum observed plasma drug concentration (tmax) of TEV-56286Time frame: Day 1 to Day 3
  2. SAD: Maximum observed plasma concentration (Cmax) of TEV-56286Time frame: Day 1 to Day 3
  3. SAD: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of TEV-56286Time frame: Day 1 to Day 3
  4. SAD: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of TEV-56286Time frame: Day 1 to Day 3
  5. MAD: tmax of TEV-56286Time frame: Day 7 to Day 9
  6. MAD: Cmax of TEV-56286Time frame: Day 7 to Day 9
  7. MAD: AUC0-t of TEV-56286Time frame: Day 7 to Day 9
  8. MAD: Area Under the Plasma Drug Concentration-Time Curve for the Defined Interval Between Doses (AUC0-tau) of TEV-56286Time frame: Day 7 to Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Teva Investigational Site 12174

    Miramar, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.